Introduction
Highly active antiretroviral therapy (HAART) has been credited with significant improvements in human immunodeficiency virus (HIV)-related morbidity and mortality and decreases in HIV-related hospitalizations. [1] [2] [3] [4] However, after initial decreases in hospital admissions amongst HIV-infected patients, some researchers have noted a plateau in hospitalization rates and even small increases. 5, 6 Reports have suggested that hospitalization patterns may be shifting in HIV-infected populations due to opportunistic infections and AIDS-related disease to admissions related to complications such as adverse drug events, HCV, and other comorbidities. 3, 7 Outcomes such as hospitalization affect patient's quality of life and can indicate poor health and increased risk of mortality. 8, 9 In a report entitled, Adherence to Long-Term Therapies: Evidence for Action the World Health Organization (WHO) states: ''across diseases, adherence is the single most modifiable factor that compromises treatment outcome. '' 10 Adherence to HAART is an essential component of its long-term success with HIV. 11 However, although adherence rates of greater than 95% are required among HIV-infected adults for optimal clinical outcomes, 12 in reality these rates are reported to be much lower. Most studies report that 40-60% of patients are less than 90% adherent to HAART. 13 Suboptimal levels of adherence result in fewer clinical benefits in terms of immunological and virological variables and contribute to the development of antiretroviral resistance 14, 15 and higher mortality. 16, 17 Whether a patient is adherent to their medications appears to be influenced by a range of medical and social determinants such as regimen complexity, patient-related factors, psychosocial issues, patient belief systems, and patient-provider relationship. 18 Adherence has also been found to decrease over time and to vary depending on type of regimen prescribed. 19, 20 Although the relationship between adherence and mortality or emergence of drug resistance has been well characterized, the relationship between adherence and hospitalization has yet to be explored. In theory, HAART may impact hospitalizations through a variety of mechanisms. Poor adherence may increase rates of hospitalization due to unrealized treatment benefits and a corresponding decline in health status. Conversely, at least in the short term, poor adherence could lead to fewer hospitalizations by decreasing the risk of drug toxicities, resistance, and adverse events associated with use of HAART. The purpose of this study, therefore, was to assess the impact of adherence on the hospitalizations in a Canadian cohort of patients taking HAART.
Materials and Methods
The HIV/AIDS Drug Treatment Program (DTP), operated through the British Columbia (BC) Centre for Excellence in HIV/AIDS, distributes antiretroviral medications at no cost to HIV-infected individuals prescribed therapy in the province. Antiretroviral medications are prescribed according to guidelines generated by the BC Therapeutic Guidelines Committee, 21 consistent with those published by the International AIDS Society-USA. [22] [23] [24] The DTP has received ethical approval from the necessary Institutional Review Boards. Patient's demographics (age, gender, intravenous drug use), relevant medical information (physician experience, previous hospitalization), characteristics of the infection (CD4 count, viral load, and AIDS at baseline), and prescribed therapies were recorded at baseline. Intravenous drug use was defined as ever having used injection drugs. An AIDS diagnosis at baseline was defined according to the Health Canada guidelines at time of therapy initiation. Physician experience was estimated for each participant's first follow-up physician and was defined as the cumulative number of HIV-infected persons under the physician's care by the date of the participant's first known eligibility, and was measured in increments of 100 patients. 26 Adherence was estimated based on the time that antiretroviral drugs dispensed would last as a proportion of the follow-up time during the patient's first year on therapy (prescription refill or prescription compliance). 27 Previous studies have shown that this estimate strongly predicts virological response and survival. [28] [29] [30] Adherence was examined as a dichotomous variable using the established cut point of 95% adherence.
Hospitalization information was obtained by linking the HOMER data with patient records from the BC Ministry of Health. 28 A hospitalization event was defined as admission to any BC hospital for one or more days. Participants were followed from the time they started HAART until March 31, 2002 . Individuals with no hospitalization date were censored at last contact date or on date of death, determined by linking with vital statistics data.
Demographics and infection-related characteristics of adherent and nonadherent participants were compared using 2 tests for categorical variables and Wilcoxon rank sum test for continuous variables. Time to first hospitalization was determined, and demographic and clinical characteristics were examined using Cox proportional hazard models. Statistical analyses were performed using SAS software version 6.0 (SAS, Cary, NC).
Results
Among the 1605 HOMER participants, 42% (n ¼ 672) had at least one hospitalization postinitiation of HAART therapy. The median age of the population was 38 (IQR: 32, 44). The median follow-up time was 25.1 months (IQR: 10.1, 42.5). Among those with no record of hospitalization, 5% (n ¼ 43) were censored at death. Ten participants were excluded from the study due to insufficient information to link with hospitalization data. Only 2 participants were excluded from the final model due to a lack of study data. Median adherence levels were 92 (IQR: 58, 100) in hospitalized group and100 (IQR: 83, 100) in nonhospitalized group. Table 1 displays the characteristics of participants, stratified by adherence category (adherent >95%, nonadherent <95%). A significantly larger proportion of nonadherent patients were hospitalized during the study period (P < .001). When compared to the nonadherent category, adherent patients were more likely to be male (P < .001), older (P < .001), and to have started HAART with an AIDS diagnosis (P < .001), to have higher CD4 counts (P < .01) and a more experienced physician (P < .001). Adherent patients were significantly less likely than nonadherent patients to have been hospitalized in the 6 months prior to baseline (P < .001) or to have ever injected drugs (P < .001). There were no significant differences in viral load or treatment regimen [nonnucleoside reverse transcriptase inhibitor vs. protease inhibitor (NNRTI vs. PI)]; however, although only a small number of patients were on a boosted PI regimen (5%), a higher proportion of these patients were >95% adherent (70% vs. 56% of those on nonboosted PI regimen; P ¼ .02). The relationship between adherence and hospitalization was similar across regimens [unadjusted OR (95% CI) for NNRTI: 2.3 (1.6-3.3), for PI: 2.6 (2.0-3.4), and for boosted PI: 4.3 (1.6-11.4)].
Kaplan-Meier survival curves for time to hospitalization are shown in Figure 1 . The difference in the rates of hospitalization between adherent and nonadherent patients is apparent, with half of nonadherent patients having a hospitalization event within the first 2 years. Table 2 describes the overall adjusted model. Nonadherence (<95%) remained predictive of hospitalization, regardless of whether PI regimen was added to the model. There was not enough power to examine the possibility of an interaction between boosted regimens and adherence. Those who were nonadherent were 1.88 times (95% CI: 1.60-2.21) more likely to experience a hospitalization event. Previous hospitalization, female gender, high viral loads, low CD4 count levels, and intravenous drug 
Discussion
Our results demonstrate that nonadherence independently predicts hospitalization of HIV-infected patients initially prescribed triple therapy. In our cohort of over 1600 people prescribed HAART, those with less than 95% adherence had 1.88 times higher risk for hospitalization than those with higher adherence (>95%). Although few studies have examined this association between adherence and hospitalization, Paterson et al 31 demonstrated similar results in a sample of 99 HIV-infected patients attending clinics in Pennsylvania and Nebraska from 1997-1999. Those patients with 95% adherence had fewer days in the hospital (2.6 days per 1000 days of follow-up) than those with less than 95% adherence (12.9 days per 1000) measured using microelectronic monitoring systems.
This increased risk of hospitalization when adherence drops below 95% is consistent with the mortality and drug resistance literature. The magnitude of adherence required not only to maintain viral suppression but also to prevent the development of drug resistance has been estimated to be at least 92% to 95%. 32 In terms of clinical outcomes, a 10% decrease in adherence has been associated with a doubling of HIV RNA 33 and a 16% increase in mortality. 34 In an earlier study of this study cohort (HOMER), Hogg et al 29 found that cohort participants using ART <75% of the time in the first year were three more likely to die than those with higher adherence levels.
The results of this study would suggest that not only should HIV be detected and treated in a timely fashion but that hospitals may provide a key setting for the provisions of referrals (eg, adherence counseling) and interventions to enhance adherence through support and education. Several strategies to improve adherence have been extensively discussed in the literature. 13, 18, 35 These may include involvement of patients in health care decisions, multidimensional educational programs, and instruction in behavioral skills to enhance adherence. Other strategies that have been shown to be effective include engaging peers and offering financial incentives. 36 Programs that involve directly observed therapy (DOT) in addition to enhanced tailored services have been successful in attaining high rates of adherence to HAART. 10 Nevertheless, the continued lack of women-centered services for HAART has been shown to be a major barrier to accessing treatment among vulnerable female populations. 37 The decreased adherence among women and intravenous drug users seen here may also reflect a similar lack of support for staying on treatment once HAART is accessed. Additional strategies targeting women and intravenous drug users are called for with results like those of our study, as are continuing education programs for service providers. Communities can work collectively to address the systemic-level barriers to achieving high levels of antiretroviral adherence such as poverty, enforcement policies, stigmatization, and lack of adequate harm reduction initiatives and treatment access for people with addiction. As some literature has noted a shift in the reasons for hospitalization, with an increase in visits due to side effects of HAART, 3, 6 we examined categories of adherence to assess this possibility. In theory, one might expect to see a convergence of survival curves for those above 95% adherence and those in lower categories, where poor outcomes due to side effects begin to emerge and equate the risk for poor outcomes due to nonadherence. There was, however, no difference in any of the survival curves for those below 95% adherence, and participants with >95% adherence were consistently at lower risk of hospitalization over the follow-up period.
With our relatively conservative adherence criteria, 58.8% of the cohort were adherent (95%) as compared to 41.3% classified as nonadherent (<95%). This is relatively low yet consistent with nonadherence rates between 30% and 80% that have been found by others in both clinical trials and clinical practice settings. 19 In this study as in others, adherence was influenced by a range of demographic and psychosocial variables. Recent results from the Swiss HIV Cohort Study showed that younger age, lack of social support, and complexity of therapy are important factors that are related to nonadherence with HAART. 19 Other factors consistently associated with nonadherence include symptoms and medication side effects, negative life events, and psychological characteristics such as self-efficacy. 38 According to the WHO taxonomy, 10 correlates of nonadherence can be categorized as socioeconomicrelated factors, patient-related factors, condition-related factors, treatment-related factors, and systemrelated factors. As part of this study, we were able to examine the patient-related factors of age, gender, intravenous drug use, and previous hospitalization; the condition-related factors of CD4 count, viral load, and AIDS status; and treatment-related factors of HAART regimen (PI or NNRTI-based), and physician experience. Unfortunately, socioeconomic and system related factors were beyond the scope of this study. In this study, individuals who were nonadherent to their medications were more likely to be younger, to have had a previous hospitalization, to have used intravenous drugs, to have not had AIDS at baseline, to have lower CD4 levels, and to have a less experienced physician.
Other studies have found an association between adherence to HAART and female gender, younger age, or active drug use but this remains controversial in the literature. 38, 39 A recent study from this cohort found that there were gender differences in HIV-RNA rebound rates among active intravenous drug users, but that this was not seen among nonintravenous drug use participants. 40 Reasons for women being less adherent may include genderbased barriers to help-seeking related to factors such as lack of adequate childcare or abuse/violence. 37, 41 Another BC study found that close to half of intravenous drug users discontinue HAART within the first year of therapy due to factors such as recent incarceration, negative outcome expectations, efficacy expectations, and self-regulatory efficacy. 42 In addition, there is a high prevalence (>95%) of hepatitis C virus infection among intravenous drug users in BC, which has been shown to affect ability to adhere to HAART. 43 In this study, physician experience was associated with adherence (95%) and was also protective against hospitalization. Research has shown that increased physician experience with HIV and AIDS, not specific training per se, is the most important factor associated with the successful treatment of HIV-infected patients. 18, 31, 44, 45 Experience with HIV-infected individuals may help to generate better patient rapport and tailored treatment, leading to better adherence and fewer hospitalizations.
One limitation of this study is that no data were available on causes of hospitalization, which limits our ability to interpret the increases in the proportion of HIV-infected patients hospitalized. The potential for confounding by indication, whereby physicians are more likely to hospitalize patients they know are nonadherent, tempers the ability to draw conclusions around the causality of nonadherence leading to worse outcomes and hospitalization; however, regardless of the pathway, these findings still indicate that programs aimed to increase adherence to HAART could lead to fewer hospitalizations, and that hospitals could be useful settings to identify patients in need of adherence support. Using prescription refills to measure adherence also presents possible limitations as it does not measure pill counts directly but assumes that drugs prescribed are taken as prescribed. Also, adherence was based on the first year of follow-up, which previous studies have shown reflects subsequent years 29 ; however, changes in adherence patterns could result in misclassification.
Despite the limitations, this study examines the impact of adherence on hospitalization morbidity, which is a neglected area of research. Also, the province-wide sample of HIV-infected individuals with free access to antiretroviral medications eliminates the impact of cost of medications on adherence patterns. In addition to creating and maintaining other supportive and educational community and clinical contexts for HIV-infected patients, hospitals are ideal settings for comprehensive interventions aimed at improving HAART adherence.
Adherence levels of at least 95% led to fewer hospitalizations among HIV-infected individuals who initiated HAART with no previous exposure to HIV antiretrovirals. Clinical and social variables that were associated with nonadherence in this study included younger age, previous hospitalization, history of intravenous drug use, AIDS at baseline, lower CD4 levels, and having a less experienced physician. In addition to creating and maintaining other supportive and educational community and clinical contexts for HIV-infected patients, hospitals are ideal settings for comprehensive interventions aimed at improving HAART adherence.
